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Abstract
Viruses rely on the metabolic network of the host cell to provide energy and macromolecular precursors to fuel viral
replication. Here we used mass spectrometry to examine the impact of two related herpesviruses, human cytomegalovirus
(HCMV) and herpes simplex virus type-1 (HSV-1), on the metabolism of fibroblast and epithelial host cells. Each virus
triggered strong metabolic changes that were conserved across different host cell types. The metabolic effects of the two
viruses were, however, largely distinct. HCMV but not HSV-1 increased glycolytic flux. HCMV profoundly increased TCA
compound levels and flow of two carbon units required for TCA cycle turning and fatty acid synthesis. HSV-1 increased
anapleurotic influx to the TCA cycle through pyruvate carboxylase, feeding pyrimidine biosynthesis. Thus, these two related
herpesviruses drive diverse host cells to execute distinct, virus-specific metabolic programs. Current drugs target nucleotide
metabolism for treatment of both viruses. Although our results confirm that this is a robust target for HSV-1, therapeutic
interventions at other points in metabolism might prove more effective for treatment of HCMV.
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Introduction
Herpesviruses are large, enveloped, double-stranded DNA
viruses, capable of both lytic infection and life-long latency in
mammalian hosts [1]. They are major causes of human disease. A
majority of adults are infected with herpes simplex virus 1 (HSV-1)
and/or human cytomegalovirus (HCMV). An alpha-herpesvirus,
HSV-1 infects a wide range of organisms and cells types, causing
symptoms ranging from cold sores to encephalitis. The prototypical
beta-herpesvirus, HCMV, selectively infects non-transformed hu-
man cells. Although frequently asymptomatic, HCMV causes severe
disease in neonates and immunocompromised adults. All herpesvi-
ruses encode metabolic enzymes in their genomes, primarily ones
involved in nucleotide metabolism. The HSV-1 genome encodes a
viral thymidine kinase, ribonucleotide reductase, dUTPase and
uracil DNA glycosylase, while HCMV encodes a functional form of
uracil DNA glycosylase [2]. Like all viruses, however, they rely
primarily on the metabolic capabilities of their cellular hosts for
replication. Specifically, the host provides the energy, amino acids
and lipids, as well as most nucleotides, required by the virus.
Improved technologies for measuring both enzymes and
metabolites is enabling for the first time in-depth analysis of
virus-host cell metabolic interactions. Liquid chromatography
coupled to mass spectrometry (LC-MS) facilitates direct measure-
ment of a large number of cellular metabolites [3,4]. Combined
with isotope tracers, metabolic flows (fluxes) can also be
determined. These new tools have revealed that, rather than
passively relying on basal host cell metabolic activity, many viruses
actively redirect host cell metabolism [5,6,7]. For example,
hepatitis C virus up-regulates host cell glycolysis and modulates
concentrations of specific lipids [8]. Similarly, hepatitis B virus
replication perturbs cholesterol metabolism by inducing increased
7-dehydrocholesterol levels [9].
Among herpes viruses, the metabolic effects of HCMV have
been the most extensively studied. Infection of a human fibroblast
cell line with HCMV leads to two-fold increases in glycolytic
activity and nucleotide synthesis, as well as yet greater increases in
citric acid cycle flux and lipid biosynthesis [10]. Consistent with
HCMV’s reliance on the metabolic fluxes that it induces,
inhibition of the committed step of fatty acid synthesis and
elongation, acetyl-CoA carboxylase, blocks HCMV replication
[10]. The virus also induces an increased dependence on
glutamine that serves to drive the TCA cycle [10,11]. These
metabolic changes are only partially accounted for by increased
levels of enzyme transcripts, indicating the involvement of multiple
regulatory mechanisms [6].
A limitation of studies of virus-host metabolic interactions to
date is that they have focused on single virus-host cell pairs.
Moreover, they have often employed transformed host cells that
differ markedly from the cells usually infected in vivo. This has
precluded understanding whether the observed metabolic effects
of viruses are relevant in their natural host cells, preserved across
host cell types, and conserved within families of related viruses. To
address these issues, here we compare and contrast the metabolic
effects of HCMV and HSV-1, across both fibroblast and epithelial
host cells. Specifically, we studied the laboratory-adapted AD-169
strain of HCMV, which is restricted to growth in fibroblasts, and
whose metabolic effects have been previously studied [6,10]. In
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TB40/E, which grows in many cell types, to study the infection of
epithelial cells [12]. For HSV-1 infections, we chose the highly-
passaged, non-neuroinvasive KOS 1.1 strain and a prototypical
neuroinvasive strain, the F strain [13,14]. Both primary human
foreskin fibroblasts and the MRC5 fibroblast cell line were
analyzed after infection by both viruses. HSV-1 infection was also
studied in the Vero African green monkey renal epithelial cell line
which is traditionally used for its growth. Given HCMV’s
propensity to cause retinitis [15], it was studied in the ARPE-19
retinal pigment epithelial cell line.
Using LC-MS to probe core metabolite concentrations and
fluxes, we find that HCMV and HSV-1 both trigger major
metabolic changes in their cellular hosts, and that these changes
are similar across different host cell types and for different strains
of the same virus. In contrast, the effects of HCMV and HSV-1
diverge markedly. HCMV most greatly impacts pathways
generating substrates for lipid metabolism, whereas HSV-1 most
greatly impacts deoxypyrimidine metabolism.
Results
HCMV and HSV-1 trigger distinct metabolome changes
We examined the metabolic changes triggered by infection of
fibroblast and epithelial host cells with HCMV and HSV-1.
Fibroblasts (HFF and MRC5) were held at confluence for 3–5 days
then serum-starved for 24 hours prior to infection, while epithelial
cells (ARPE19 and Vero) were infected at 80–90% confluence and
maintained in the presence of dialyzed serum at all times. As a
consequence the fibroblast host cells were growth arrested at the
time of infection, while the epithelial cells continued to replicate
after mock inoculation [16]. Consistent with their different growth
states, there were substantial differences in the metabolome of the
host cells prior to infection, with compounds directly involved in
proliferative processes such as carbamoyl-aspartate (pyrimidine
biosynthesis), dTTP (DNA synthesis), and S-methyl-59-thioadeno-
sine (polyamine synthesis) markedly higher in the growing
epithelial cells than the quiescent fibroblasts (Figure S1). Other
compounds, such as those involved in mitochondrial fatty acid
oxidation (carnitine and acetyl-carnitine), were higher in growth
arrested fibroblasts compared to growing epithelial cells.
Infections were performed at a multiplicity of 3 pfu/cell to
ensure near complete exposure of the cell population. Cultures
infected with one of the virus strains, or treated with a virus-free
mock inoculum, were grown in parallel and sampled at regular
time intervals from the beginning of infection until peak virus
yields were achieved. Medium was changed every 24 h to ensure a
consistent nutrient supply to the cells; lack of media changes in
earlier work [6] resulted in some different metabolite patterns from
those observed here. In particular, we find that citrate and malate
levels increase .10-fold during HCMV infection, compared to the
2-fold change seen in previously published work [6]. Maximum
virus output was reached at around 24 h post infection (hpi) in
HSV-1 infected cells, and around 96 hpi HCMV infected cells
(Figure S2).
Over 80 metabolites were identified and detected in all
experiments. Relative concentrations of these species, between
infected and mock-infected cells, are shown in Figure 1 (for blue/
yellow version of the heat map, see Figure S3; for source data, see
Table S1). A third of the compounds were measured by both high
resolution mass spectrometry (orbitrap) and triple quadrupole
mass spectrometry (QQQ). The profile of any single metabolite
detected in multiple LC-MS methods was found to be similar, as
indicated by co-clustering of the associated data in almost all cases
(Figure 1).
Both viruses triggered .4-fold changes in the levels of roughly
half of the metabolites assayed. Among the metabolites changing
markedly, those increasing outnumbered those decreasing roughly
two-to-one. Although the magnitude of the changes in compound
levels depended on the host cell, typically being smaller in the
growing epithelial cells, the majority of the trends were host cell
invariant. This is remarkable given the differing initial growth and
metabolic states of the host cells, and it indicates a robust ability of
the viruses to re-program metabolism.
Extracting major trends from the dataset by singular value
decomposition [17] resulted in two characteristic vectors that
accounted for .10% of the information in the dataset (Figure
S4A). These vectors represent prototypical metabolite response
patterns. The first vector accounts for 16% of the variation in
metabolite levels over the time courses. In this vector, the signal as
a function of time shows a similar trend in each of the time
courses, thus representing a generic metabolite concentration
response to herpesvirus infection (Figure S4B). The smaller signal
in the first and last columns corresponding to the infections of
epithelial cells reflects the smaller fold-changes in metabolite levels
induced by viral infection in the growing epithelial cells compared
to growth arrested fibroblasts. The strongest contributor to the
generic infection response is dTTP, whose upregulation is
consistent with the shared need of both viruses to replicate their
DNA. The second vector, accounting for 12% of the variation in
the dataset, represents a virus-specific response with opposing
patterns for the HCMV and HSV-1 infection time courses (Figure
S4B). Key contributors to this virus-specific response include TCA
cycle intermediates, consistent with their rise during HCMV but
not HSV-1 infection, and the nucleotides dUMP and dTMP,
consistent with their rise during HSV-1 but not HCMV infection.
The third most significant vector, which accounts for 6% of the
information in the dataset, represents a metabolic response
characteristic of Vero cells (Figure S4B). While most of the
changes proved to be host cell-independent, the third vector draws
attention to the impact of different host cell types on the metabolic
effects of viruses. The strongest contributors to this vector are
Author Summary
Enveloped viruses draw on cellular machinery and
materials to generate copies of their genome, structural
proteins, and membrane. These biosynthetic processes use
the host metabolic network to provide energy and small-
molecule precursors. We have investigated how two
important enveloped viruses, human cytomegalovirus
and herpes simplex virus-1, alter host metabolism to
provide materials for viral replication. We show that rather
than passively relying on basal host cell metabolic activity,
both viruses actively redirect host cell metabolism,
implementing divergent metabolic programs that are
robust to host cell type and virus strain. Human
cytomegalovirus enhances lipid biosynthesis, while herpes
simplex-1 gears central carbon metabolism toward the
synthesis of pyrimidine nucleotides. Consistent with these
changes, human cytomegalovirus is more sensitive to
inhibition of fatty acid synthesis and herpes simplex virus-1
to inhibition of central metabolic reactions leading
towards pyrimidine synthesis. As these two closely related
viruses have divergent metabolic strategies, and since the
metabolic perturbations point to potential drug targets, an
important priority is defining the metabolic programs of
other viruses.
Divergent Herpes Virus Metabolic Impact
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depletion in infected Vero cells in contrast to their accumulation
in all other cell types. The remaining characteristic vectors
account for the other 66% of the information. This large amount
of residual information reflects a myriad of metabolite, virus, and
cell-type specific dynamics. For example, proline and glycine-
betaine showed cell type-specific upward or downward trends.
Other metabolites, such as dTTP, showed different dynamic
response patterns across different host cell types.
In all cell types tested, HCMV infection induced phosphoenol-
pyruvate, deoxypyrimidine triphosphates, CDP-choline, and
acetylated amino acids, as well as a striking and coordinated
increase in citrate, malate and other TCA cycle intermediates
(Figure 1). Depleted compounds included glycerophosphoinositol,
taurine, and a number of pentose phosphate pathway metabolites.
On the other hand, HSV-1 triggered increased levels of pentose
phosphate pathway intermediates, as well as glycolytic intermedi-
ates, and deoxypyrimidines (Figure 1). Notably depleted com-
pounds included glycine betaine, taurine, creatine, and NAD+.
The conserved decrease in the osmolyte, taurine, in both HCMV
and HSV-1 likely reflects a host cell response to virus-induced
increases in cell volume [18]. Glycolysis, the citric acid cycle, and
pyrimidine biosynthesis are discussed in greater detail below.
Glycolytic flux during HCMV and HSV-1 infection
Glycolysis and the TCA cycle form the backbone of central
carbon metabolism in mammalian cells. Through these two
pathways glucose is either oxidized to produce energy in the form
of NADH and ATP, or converted to precursors of amino acids,
lipids and nucleotides. The levels of glycolytic intermediates are
altered in a strikingly different manner during HCMV and HSV-1
infections (Figure 2A). The concentrations of metabolites in lower
glycolysis increase during HCMV infection, while levels of upper
glycolytic intermediates drop. Conversely, in response to HSV-1
infection the opposite occurs. While these concentration measure-
ments are informative, it is not possible to deduce whether changes
in influx, efflux or a combination of both are responsible for the
perturbations of the metabolite levels. Neither the turnover rate of
a metabolic intermediate, nor the material flow through a
pathway, can be predicted based on metabolite pool sizes alone.
To understand how material flow, i.e., flux, is altered, further
assays must be employed.
In cultured mammalian cells, the enzyme-catalyzed reactions of
glycolysis convert the bulk of glucose imported from the
extracellular environment to lactate, which gets excreted. Thus,
changes in the rate of material flow through glycolysis can be
approximated by measuring the rate of glucose consumption and
lactate production. We determined the glucose uptake and lactate
excretion rates in infected and mock treated HFFs by directly
measuring the amount of glucose and lactate in the extracellular
medium over time (Figure 2B). HCMV increased the uptake of
glucose (p=0.02) and the excretion of lactate (p=0.0006), in
agreement with previously published results on HCMV-infected
fibroblasts [10,19,20] (Figure 2B). On the contrary, in HSV-1
infected cells the glucose uptake (p=0.21) and lactate excretion
(p=0.002) rates decreased to a modest extent.
In addition to glucose from the medium, glycolysis can also be
fueled by glucose acquired from the breakdown of stored glycogen.
Moreover, decreased lactate production can reflect increased
glycolytic efflux to the TCA cycle, rather than decreased glycolytic
flux. To confirm our conclusions based on the glucose and lactate
measurements, we also measured the rate of incorporation of
isotope-labeled nutrients into downstream metabolites. Following
a switch to labeled media, metabolite pools become progressively
more labeled, with the unlabeled fraction exhibiting an exponen-
tial-type decay. Flux through a metabolite is the product of the
rate of this decay and the total pool size of the metabolite [21]. To
reliably estimate this decay rate, it is important to obtain samples
at early time points where the fractional labeling is changing
rapidly. Because label from glucose gets incorporated very quickly
into glycolytic intermediates, measurements at later time points are
likely to reflect steady-state labeling fractions, not labeling rates per
se. At steady state, the amount of labeled metabolite reflects the
total metabolite pool size and the fraction of its production from
the labeled substrate, but not the rate of labeling.
To characterize glycolytic flux, we switched HCMV and HSV-1
infected cells, as well as their mock-treated counterparts, to
13C-
labeled glucose containing media, and used LC-MS to monitor the
labeled forms of downstream metabolites over time. HCMV
infection increased the fractional labeling rate of glycolytic
intermediates fructose-1,6-bisphosphate and dihydroxyacetone
phosphate, while HSV-1 decreased it (Figure 2C). The decrease
in the rate of HSV-1 labeling was complemented by a corres-
ponding increase in metabolite concentration. Thus, we can
conclude that HCMV significantly increases flux through
glycolysis and HSV-1 does not.
Interestingly, in HSV-1-infected cells the metabolites upstream
of phosphoenolpyruvate build up, while the ones downstream
drop (Figure 2A). This suggests a bottleneck in glycolytic efflux at
the step catalyzed by pyruvate kinase, the enzyme that converts
phosphoenolpyruvate and ADP to pyruvate and ATP. The
buildup of glycolytic metabolites upstream of pyruvate is
accompanied by increased levels of pentose phosphate pathway
intermediates, thus increasing the availability of ribose-phosphate
for the synthesis of nucleotides. During hepatitis C infection the
levels of most glycolytic enzymes were shown to be elevated, with
the notable exception of pyruvate kinase [8]. Such changes in
enzyme levels may lead to a similar metabolic outcome as
observed in HSV-1 infected cells. However, as the activity of
glycolytic flow is under tight allosteric control [22], direct
metabolic analysis of hepatitis C is warranted to confirm this.
TCA cycle influx during HCMV and HSV-1 infection
The metabolites of the TCA cycle showed a particularly
interesting difference in labeling patterns when HCMV- and
HSV-1-infected fibroblasts were supplied with uniformly labeled
13C- glucose. In the uninfected, growth arrested fibroblasts, citrate
was only minimally labeled over a 2 h time period (Figure 3D, top
Figure 1. Divergent metabolic profiles of HCMV- and HSV-1-infected cells. Metabolite levels during the course of HCMV and HSV-1
infection, normalized by packed cell volume and expressed relative to levels measured in the equivalent mock-treated host cells. Ratios are log
transformed and plotted on a color scale. Rows correspond to metabolites measured either by LC-high resolution MS or LC-triple quadrupole MS/MS
(those measured by triple quadruople are marked ‘‘QQQ’’). Columns correspond to hours post infection for each of the eight infection time courses.
The host cells and virus strains used in each time course are indicated. HCMV (strains TB40/E and AD169) and HSV-1 (strains KOS and F) were used to
infect growing epithelial (ARPE19 and Vero) and growth arrested fibroblasts (HFF and MRC5). During HCMV infection samples were taken at 3, 24, 48,
72, 96 hpi, and also at 120 hpi during the infection of ARPE19 cells with the TB40/E strain. During HSV infection samples were collected at 3, 6, 9, 12,
15, 18, 21, and 24 hpi. Values are averages of duplicate independent biological experiments. To view the same figure in blue-yellow color scale, see
Figure S1.
doi:10.1371/journal.ppat.1002124.g001
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significant amount of citrate with two labeled carbon atoms (
13C2-
citrate) (Figure 3D, center panel), while their HSV-1-infected
counterparts generated citrate with three labeled carbons (
13C3-
citrate) (Figure 3D, bottom panel). These two forms of citrate are
produced by different pathways, which are selectively up-regulated
in a virus-specific manner.
Labeled carbon atoms derived from
13C-glucose can enter the
TCA cycle via two routes (Figure 3A). In one, pyruvate
dehydrogenase and citrate synthase incorporate two carbons from
glucose into citrate via acetyl-CoA (Figure 3B). The labeling
pattern of citrate during HCMV infection indicates increased
influx of glycolytic carbon to the TCA cycle via this route
(Figure 3D). This pathway indicates a catalytic use of the TCA
cycle, with the two-carbon units originating from glycolysis either
oxidized to produce energy by complete turning of the TCA cycle,
or diverted from the mitochondria to the cytosol through the
citrate shuttle, where the acetyl group is freed for fatty acid
synthesis and/or elongation. Global flux analysis on HCMV
infection showed that both of these uses of glycolytic carbon are
up-regulated by HCMV in MRC5 cells [10]. Our results indicate
that HCMV infection of HFFs leads to the same up-regulation.
Carbon from glycolysis can also enter the TCA cycle via
pyruvate carboxylase, which converts pyruvate to oxaloacetate
(Figure 3C). All three labeled carbons in pyruvate are retained in
oxaloacetate, which is converted to
13C3-citrate, malate, or
aspartate. The labeled forms of TCA cycle intermediates observed
in HSV-1-infected cells indicate an up-regulation of carbon influx
via pyruvate carboxylase as reflected by the labeling of citrate
(Figure 3D, right panel) and malate (Figure S5) when cells are
supplied with
13C6-glucose. Furthermore, no citrate is detected
with two or five labeled carbons in these cells. Thus, unlike in
HCMV-infected cells, the use of glucose to drive the citrate shuttle
and ensuing fatty acid synthesis is minimal during HSV-1
infection. The previous metabolic analysis of HCMV infection
led to the recognition of a potential new drug target by showing
that de novo fatty acid biosynthesis is essential for HCMV
replication [10]. Pharmacological inhibitors of enzymes in fatty
Figure 2. Perturbation of glycolysis by HCMV and HSV-1. (A) Plots of individual metabolite abundance during HCMV and HSV-1 infection.
Data are the same as presented in Figure 1. Metabolite concentrations are expressed relative to equivalent mock-treated cells. Rows correspond to
infection time courses of the following virus strains and cell types: (i) TB40-HFF, (ii) AD169-HFF, (iii) AD169-MRC5, (iv) TB40-ARPE19, (v) F-HFF, (vi) KOS-
HFF, (vii) KOS-MRC5, (viii) KOS-Vero. Columns correspond to time points: 3, 24, 48, 72, 96 hpi for HCMV and 3, 6, 9, 12, 15, 18, 21, 24 hpi for HSV-1
(Hexose-P: glucose-6-phosphate and its isomers; FBP: fructose-1,6-bisphosphate; DHAP: dihydroxy acetone-phosphate; PEP: phosphoenolpyruvate).
(B) Measurement of glucose uptake and lactate excretion rates in HCMV-AD169 or HSV-KOS infected, as well as mock-treated, human foreskin
fibroblasts (mean 62 s.e.; n=3). (C) Buildup of the labeled fraction of the FBP and DHAP pools after switching cells to uniformly
13C-labeled glucose
medium at 12 hpi during HSV-KOS or 48 hpi during HCMV-AD169 infection or equivalent virus-free treatment of HFF cells. Symbols indicate
experimental data points 62 s.e.; n=2; lines indicate exponential fit.
doi:10.1371/journal.ppat.1002124.g002
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PLoS Pathogens | www.plospathogens.org 5 July 2011 | Volume 7 | Issue 7 | e1002124Figure 3. Virus-specific up-regulation of glucose influx to the TCA cycle. The left column of schematic show carbon labeling from glucose to
the TCA cycle via pyruvate carboxylase and pyruvate dehydrogenase. Red dots denote
13C atoms originating from uniformly
13C-labeled glucose. (A)
Labeling patterns when neither pyruvate carboxylase nor pyruvate dehydrogenase are active. (B) Labeling pattern when carbon influx to the TCA
cycle from glucose is via pyruvate dehydrogenase. (C) Labeling pattern when carbon influx to the TCA cycle from glucose happens via pyruvate
Divergent Herpes Virus Metabolic Impact
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replication, but also the replication of influenza, an evolutionarily
divergent virus [10]. De novo fatty acid biosynthesis does not appear
to bear the same importance for the replication of HSV-1 as for
HCMV (Figure 3D). This is reflected in the lower sensitivity of
HSV-1 replication to 5-tetradecyloxy-2-furoic acid (TOFA)
(Figure S6) [10], an inhibitor of acetyl-CoA carboxylase, the first
committed enzyme of fatty acid biosynthesis.
Pyrimidine biosynthesis during HSV-1 infection
The reaction catalyzed by pyruvate carboxylase is an anaplero-
tic reaction that serves to replenish the intermediates of the TCA
cycle as they are removed for biosynthetic purposes. However, in
spite of its up-regulation during HSV-1 infection, after an initial
elevation, the levels of TCA cycle intermediates drop (Figure 4).
This indicates that HSV-1 triggers an even greater increase in
TCA cycle efflux. Notably, the concentration of aspartate, which is
produced from oxaloacetate, decreases significantly after infection
with HSV-1. In addition to being used for protein synthesis,
aspartate is a substrate for pyrimidine nucleotide biosynthesis.
Unlike in HCMV infection, in response to HSV-1 infection the
rates of total RNA and total protein syntheses drop [23,24]. At the
same time, viral DNA synthesis increases the demand for
deoxyribonucleotides. The nucleotide precursors essential for
DNA synthesis can be acquired through salvage reactions or de
novo synthesis [25,26]. When replicating in quiescent cells as
opposed to actively dividing ones, viruses face a greater challenge
in acquiring nucleotides for viral DNA replication, because the de
novo nucleotide biosynthesis pathways are less active [27]. HSV-1
encodes a set of enzymes addressing this problem and their impact
is reflected in increased concentrations of the intermediates of the
pyrimidine nucleotide biosynthesis pathway (Figure 5). HCMV
employs an alternative mechanism whereby the host cell is driven
from quiescence to the G1/S boundary of the cell cycle [28],
stimulating host cell nucleotide biosynthesis but preventing host
DNA replication. Interestingly, in HSV-1 infected serum-starved
fibroblasts dTTP levels are not observed to peak and drop after
6 hpi as reported in Vero cells (Figure 1) [26], and BHK cells [29].
In growth arrested fibroblasts the dTTP pool continues to rise
throughout the infection (Figure 5). Such a trend was previously
observed in mutant BHK cells that lack thymidine kinase and
deoxycytidine kinase activities [29]. Confluent, serum-starved
fibroblasts may present a similar cellular environment, with very
low basal activity of DNA-biosynthetic enzymes.
Uracil can occur in DNA as a result of cytosine deamination or
misincorporation of dUTP [30]. The UL50 and UL2 genes of
HSV-1 encode enzymes that address these problems. The viral
dUTPase (UL50) serves to reduce incorporation of uracil into viral
DNA by decreasing dUTP levels and producing dUMP. Uracil-
DNA glycosylase (UL2) participates in base excision repair of the
HSV-1 genome, removing uracil from viral DNA [31,32]. These
two viral enzymes are likely responsible for the increased dUMP
and uracil levels during HSV-1 infection (Figure 5).
While there is no known HSV-1 gene that causes the increased
production of carbamoyl-aspartate, evidence for the regulation of
aspartate transcarbamoylase during adenovirus infections has been
presented in the past [33,34]. Furthermore, carbamoyl-aspartate
levels are observed to rise dramatically in both HCMV and HSV-1
infections (Figure 1) [10]. Carbamoyl-aspartate is produced by the
multifunctional CAD protein, which catalyzes the first three steps of
de novo pyrimidine biosynthesis in mammalian cells. CAD is highly
regulated by growth state-related signaling molecules, such as the
epidermal growth factor [35,36]. Epidermal growth factor receptor
hasbeenshown toplaya roleintheentryofseveral differentviruses,
and it or related signaling pathways might contribute to virally-
induced increases in carbamoyl-aspartate levels [37,38,39].
To confirm that flux from aspartate to pyrimidine nucleotides is
up-regulated in HSV-1 infection, we analyzed the labeling pattern
of the pathway intermediates after switching cells to medium
containing uniformly labeled
13C-glutamine (Figure 6A). As
glutamine contributes to anapleurosis in both mock and infected
cells, this resulted in labeling of aspartate in both cases, and thus
enabled direct comparison of pyrimidine synthesis between these
two conditions. Significantly faster labeling of the pyrimidine end-
product UTP was observed in infected cells (Figure 6B). As the
concentration of UTP is also elevated in HSV-1 infected cells, flux
from aspartate to nucleotide synthesis is markedly increased.
Taken together, the above observations indicate an upregula-
tion of flux in HSV-1 infected cells from glucose to de novo
pyrimidine nucleotide biosynthesis via the pyruvate carboxylase-
catalyzed anaplerotic and the aspartate transaminase 2 catalyzed
cataplerotic reactions of the TCA cycle (Figure 7A). In agreement
with this, small interfering RNA (siRNA) mediated knockdown of
pyruvate carboxylase and aspartate transaminase 2 inhibit HSV-1
replication, but not HCMV (Figure 7B–D).
Discussion
Viral replication depends on the energy and biosynthetic
precursors supplied by host cell metabolism. Using a mass
spectrometry-based metabolomic approach we demonstrate that
two closely related viruses, HCMV and HSV-1, implement
divergent metabolic programs (Figure 1 and Table S1). These
programs are robust to host cell type and virus strain. While
HCMV enhances glycolytic flux and the delivery of carbon from
glucose to the TCA cycle to fuel fatty acid biosynthesis, HSV-1
gears central carbon metabolism toward the production of
pyrimidine nucleotide components (Figure 8). The focus of
HSV-1, but not HCMV, on nucleotide metabolism is interesting
in light of nucleoside analogues (acyclovir and ganciclovir,
respectively) being more effective treatments for HSV-1 than for
HCMV [40]. Both compounds depend on phosphorylation by
viral kinases for their activation, and the metabolic profile of HSV-
1 infected cells reflects the activity of the virally encoded thymidine
kinase. On the other hand, the only functional HCMV kinase
(UL97) is a protein kinase and has little to no nucleotide kinase
activity [41]. This difference is reflected in the metabolome and in
the lower efficacy of the nucleoside analogues for HCMV. In
contrast, we show that TOFA, an inhibitor of the committed step
of fatty acid synthesis and elongation, preferentially targets
HCMV over HSV-1 (Figure S6).
The viruses also induce robust changes outside of core
metabolism. For example, HCMV, but not HSV-1, induces a
striking increase in acetylated amino acids (Figure 1). After HSV-1
infection, NAD+ levels dropped by a factor of about 10, but little
decline was evident after HCMV infection. We have recently
discovered that this NAD+ depletion is due to elevated poly-ADP-
ribose polymerase activity (L. Vastag, unpublished work). The
activation of poly-ADP-ribose polymerase has also been observed in
carboxylase. (D) Levels of various labeled forms of citrate expressed as percent of the total citrate pool upon switching HCMV-AD169, HSV-KOS or
mock-treated HFF cells to uniformly
13C-labeled glucose medium. HCMV infected cells were switched at 48 hpi, HSV-1-infected cells at 12 hpi. The x-
axis indicates time after switching to labeled medium (mean 61 s.d.; n=2).
doi:10.1371/journal.ppat.1002124.g003
Divergent Herpes Virus Metabolic Impact
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the significance of such observations requires further study.
Why do these two related viruses induce markedly different
changes in host cell metabolism? Both must synthesize viral proteins
and nucleic acids and both produce enveloped virions. Perhaps the
difference results in part from the markedly different speeds at
which the two viruses progress through their replication cycles.
HSV-1 produced maximal yields in fibroblasts or epithelial cells
within about 24 h, whereas HCMV did not achieve maximal yields
until about 96 hpi (Figure S2). One might speculate, then, that
HSV-1, which accumulates its DNA fairly rapidly, must elevate
nucleotide biosynthesis; in contrast, HCMV, which accumulates its
DNAovera much longertime frame,does not require sucha strong
induction (Figure 1). It is more difficult to suggest why HCMV
depends on de novo fatty acid biosynthesis morestrongly than HSV-1
(Figure S6). It is conceivable that HCMV induces the production of
new membranes to serve as a source for the virion envelope, while
HSV-1 virions are built from pre-existing membranes. Consistent
with this view, HCMV-infected cells develop a well-defined,
membranous assembly compartment during the late phase of
infection [45,46,47], but no equivalent structure has been described
within HSV-1-infected cells.
The metabolic program induced by herpes viruses could be
implemented in several ways. One potential strategy involves
perturbation of general host biochemical milieu. For example, the
HCMV UL37x1 protein elevates free intracellular calcium levels
[48], which could potentially activate glycolysis through the action
of calcium-sensitive kinases [19]. Alternatively, virus-coded gene
products could modify or interact with pivotal regulators of host
cell metabolism, e.g., the HCMV UL38 protein [49], or with
metabolic enzymes themselves to alter their activity. Yet other
strategies could involve modulation of host cell enzyme concen-
trations through mechanisms involving transcription, translation,
or protein stability. A comprehensive systems level analysis,
incorporating transcriptomic [50,51,52,53], proteomic [8], and
metabolic data should help clarify the relative significance of these
latter mechanisms.
In addition to elucidating the mechanisms underlying host cell
metabolic hijacking, an important priority is defining the
metabolic programs of other viruses. Among herpes viruses, it
will be interesting to see whether most fit either the HSV-1 or
HCMV prototype, or whether alternative programs exist. For
smaller viruses, it will be interesting to see whether their yet more
precious genome space includes instructions for extensive host cell
metabolic reprogramming. Such work holds substantial practical
value, given overarching importance of enzyme inhibitors as
antivirals and the utility of metabolomics for identifying new
antiviral targets.
Figure 4. TCA cycle metabolite levels increase in HCMV and drop in HSV-1 infected cells. Plots of individual metabolite abundance during
(A) HCMV and (B) HSV-1 infection. These data are the same as presented in Figure 1. Metabolite concentrations are expressed relative to equivalent
mock-treated cells. Rows correspond to infection time courses of the following virus strains and cell types: (i) TB40-HFF, (ii) AD169-HFF, (iii) AD169-
MRC5, (iv) TB40-ARPE19, (v) F-HFF, (vi) KOS-HFF, (vii) KOS-MRC5, (viii) KOS-Vero. Columns correspond to time points: 3, 24, 48, 72, 96 hpi for HCMV
and 3, 6, 9, 12, 15, 18, 21, 24 hpi for HSV-1.
doi:10.1371/journal.ppat.1002124.g004
Figure 5. Upregulation of pyrimidine nucleotide biosynthesis during HSV-1 infection. Individual metabolite abundance in HSV-1-infected
and mock-treated quiescent HFFs. To show separately the trend in mock versus infected cells, metabolite concentrations are expressed relative to the
average level measured in mock-infected cells at 3 h post mock treatment (mean 62 s.e.; n=2).
doi:10.1371/journal.ppat.1002124.g005
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Cells and viruses
Primary human foreskin fibroblasts (HFFs) were collected
previously [54] and stored in liquid nitrogen. We used them at
passages 8–13. ARPE19 human retinal pigment epithelial cells,
Vero green monkey kidney epithelial cells and MRC5 human
embryonic lung fibroblasts were purchased from the American
Type Culture Collection. Cells were grown in Dulbecco’s modified
Eagle Medium (DMEM) with 10% fetal bovine serum, 100 mg/
mL penicillin and streptomycin (Invitrogen), and 4.5 g/L glucose.
HSV-1 strain F [55] was kindly provided by B. Roizman
(University of Chicago), the HSV-1 KOS 1.1 strain [56] was a
gift from D. Hargett (Princeton University), and both viruses were
grown in Vero cells [57]. BADwt-GFP is a phenotypically wild-
type HCMV laboratory strain that was generated from a bacterial
artificial chromosome (BAC) clone of strain AD169 [58]
engineered to express green fluorescent protein [59]. TB40/E-
eGFP is a phenotypically wild-type HCMV clinical isolate that was
derived from a bacterial artificial chromosome termed TB40-
BAC4 [60] containing a green fluorescent protein marker gene
under control of the SV40 promoter between US34 and TRS1.
HCMV strains were grown in MRC-5 cells. To prepare virus
stocks for both HSV-1 and HCMV, the media of infected cells was
layered over a sorbitol cushion (20% sorbitol, 50 mM Tris-HCl,
pH 7.2, 1 mM MgCl2) and virus was pelleted by centrifugation
(20,000 rpm, 1 h, 4uC, Beckman SW28 rotor). Virus stocks were
prepared in DMEM with 0.5% bovine serum albumin and
without fetal bovine serum, to avoid serum stimulation of the
growth arrested fibroblasts during inoculation.
For analysis of metabolites, fibroblasts (HFFs or MRC5) were
grown to confluence and maintained in the presence of serum for
5 d. Cells were then washed with serum-free DMEM and
maintained in serum-free DMEM for 24 h before infection or
mock treatment. Epithelial cells (ARPE19 or Vero) were grown to
80–90% confluence in DMEM with 10% dialyzed serum (Gemini
Bio-Products) before infection. At the time of infection cells were
inoculated with virus resuspended in DMEM with or without
serum. Mock treated cells were inoculated with equivalent, virus-
free DMEM. After a 1 h inoculation fresh DMEM was added to
the cells, following two washes with the appropriate medium. For
each time point in every experiment an additional mock treated
and infected plate was processed for packed cell volume
measurement. Approximately 5610
5 cells were added to packed
cell volume tubes (Techno Plastic Products), which were
centrifuged at 20006g for 5 min before reading [61]. Packed cell
volume measurements were used to normalize the metabolite
levels between samples.
Metabolite extraction
At various times post infection or addition of
13C-labeled
glucose- or glutamine-containing DMEM, the media of infected
Figure 6. Flux to pyrimidine nucleotide synthesis induced by HSV-1 infection. (A) Schematic of carbon labeling from glutamine to UTP
arising during carbon influx from glutamine to the TCA cycle. Red dots denote
13C atoms originating from uniformly
13C-labeled glutamine. (B) Plots
show the levels of the labeled form of the indicated metabolites expressed as percent of the total metabolite pool. The labeling arose upon switching
HSV-KOS infected or mock treated HFF cells to uniformly
13C-labeled glutamine media. HCMV infected cells were switched at 48 hpi, HSV-1-infected
cells at 12 hpi. The x-axis indicates time post media switch (mean 62 s.e.; n=2).
doi:10.1371/journal.ppat.1002124.g006
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(v/v) was immediately added to quench metabolism. There were
no washing steps prior to metabolism quenching, as such steps risk
metabolic alterations. Metabolites were then extracted as de-
scribed previously [21]. The extract was dried under nitrogen and
metabolites were resuspended in HPLC-grade water and centri-
fuged at 150006g speed for 5 min to remove particulate matter
before analysis. To minimize complications due to excessive
sample concentration and associated ion suppression during LC-
MS analysis, samples were diluted substantially prior to analysis:
metabolites collected from 10
6 cells (a confluent 60 mm plate of
fibroblasts) were resuspended in 500 mL water.
Figure 7. HSV-1 replication is inhibited by reducing flux from glucose toward pyrimidine nucleotide synthesis. (A) Schematic diagram
of glucose flux to pyrimidine nucleotide biosynthesis. Red lines mark siRNA-targeted reactions catalyzed by pyruvate carboxylase (PC) and aspartate
transaminase 2 (GOT2). (OAA: oxaloacetate, AKG: oxoglutarate, Gln: glutamine). (B) RNA interference knockdown of pyruvate carboxylase (marked by
arrow) in MRC5 cells. Cells were transfected with non-targeting siRNAs (NT) or siRNAs targeting pyruvate carboxylase (PC) and harvested at indicated
time points after transfection. Pyruvate carboxylase levels in the cells were detected by western blot using specific antibodies. Beta-actin was
employed as a loading control. (C) Buildup of
13C3-labeled malate after switching MRC5 cells to uniformly
13C-labeled glucose medium for 2 hours at
10 hpi of HSV-1 (F) infection. The cells have been transfected with a universal non-targeting siRNA (NT) or an siRNA targeting pyruvate carboxylase
(PC) 120 h prior to infection (significance: p=0.007). Symbols indicate experimental data points 61 s.d.; n=3; values are given in arbitrary units. (D)
Production of infectious HSV-1 (F) and HCMV (AD169) virions in cells transfected with siRNAs against pyruvate carboxylase (PC), aspartate
transaminase 2 (GOT2), or a universal negative control (NT). The transfection and infection of MRC5 cells were performed as described in Materials
and Methods. Values are expressed relative to non-targeting control (61 s.d.; n=3). Conditions resulting in significantly altered virus production
(p#0.05) compared to treatment with the universal negative control are marked with a star.
doi:10.1371/journal.ppat.1002124.g007
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To quantitatively measure the levels of metabolites in extracts
prepared from infected or mock treated cultured mammalian cells,
two different mass spectrometry methods were employed. Liquid
chromatography-tandem mass spectrometry (LC-MS/MS) in
selective reaction monitoring (SRM) mode was used to assay for
,200 metabolites of confirmed identity from a wide range of
metabolic pathways [62]. A Finnigan TWQ Quantum Ultra mass
spectrometer was used in the positive ionization mode, and a TSQ
Quantum Discovery MAX mass spectrometer in the negative
mode, each equipped with an electrospray ionization source
(Thermo Fisher Scientific). The SRMs were constructed with
parameters acquired through optimizing the collision induced
fragmentation of purified standards of the given metabolites. The
LC method in positive mode employed an aminopropyl column
for separation [62], while in negative mode the metabolite extracts
were passed through a C18 column using tributylamine as an ion
pairing agent to achieve longer retention of polar compounds
[63,64]. In addition, the LC-MS/MS method was complemented
with untargeted analysis using liquid chromatography coupled to a
stand-alone orbitrap mass spectrometer (Thermo Fisher Scientific
Exactive instrument) which performs full scans from 85 to
1000 m/z at 100,000 mass resolution [65]. In this system,
identification of compounds is based on two parameters: the
retention time on the LC column and the compound mass
measured with less than 2 ppm mass accuracy. Peaks were
identified and peak heights exported with the Metabolomic
Analysis and Visualization Engine (MAVEN) [66].
Glucose uptake and lactate excretion
For glucose uptake and lactate excretion measurements, media
samples were collected every 3 h between 45 and 57 hpi for
HCMV, and every 2 h between 6 and 18 hpi for HSV-1. The
concentrations of lactate and glucose were measured using a YSI
7100 Select Biochemistry Analyzer (YSI Incorporated). Uptake and
excretion rates were determined as the rate of concentration change
of these compounds in the media. The values were corrected using
the packed cell volume of the infected and mock cells.
Metabolic flux analysis
For experiments involving monitoring the rate of incorporation
of
13C-labeled nutrient into downstream metabolites, cells were
switched to fresh media 1 h before addition of the labeled nutrient.
This minimized the perturbation to the cells when their medium
was replaced with isotope containing medium. Cells were then
maintained in medium containing the labeled nutrient for different
lengths of time. Metabolites were extracted and various isotopi-
cally labeled forms quantified by mass spectrometry. The values
were corrected for the natural abundance of
13C as described
previously [10]. Labeled DMEM was prepared from glucose and
glutamine-free DMEM with the addition of U-
13C-glucose or
U-
13C-glutamine (Cambridge Isotope Laboratories). All media
Figure 8. Divergent effects of HCMV and HSV-1 on central carbon metabolism. Schematic summary of major metabolite concentration and
flux changes in response to HCMV (left panel) and HSV-1 (right panel) infection of growth arrested fibroblasts. Arrow colors denote flux changes and
font colors denote metabolite level changes relative to the mock-treated control (red-increased, green-decreased, grey-not detected). (Hexose-P:
glucose-6-phosphate and its isomers, Pentose-P: ribose-phosphate and its isomers, FBP: fructose-1,6-bisphosphate, DHAP: dihydroxy acetone-
phosphate, PEP: phosphoenolpyruvate, Asp: aspartate, Ala: alanine, Gln: glutamine, AKG: oxoglutarate, OAA: oxaloacetate, Ac-CoA: acetyl-
coenzymeA.)
doi:10.1371/journal.ppat.1002124.g008
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sition before use.
siRNA transfection
Double stranded siRNA molecules directed against pyruvate
carboxylase (59-GACUGUACGCGGCCUUCGATT), aspartate
transaminase 2 (59-CUAUUGAGAGCUUCACACATT), and a
Universal Negative Control (SIC001) were purchased from Sigma.
Subconfluent MRC5 cells seeded into 96-well plates were
transfected with 10 pmol of siRNA using Oligofectamine trans-
fection reagent (Invitrogen) according to the manufacturer’s
instructions. For HCMV experiments, the siRNA transfected cells
were incubated for 24 hours and then infected with HCMV strain
BADwt-GFP at a multiplicity of 0.1 pfu/cell. The cells were
further incubated for 96 hours and media containing the infectious
virus were harvested. Since HSV-1 replicates with a faster kinetics
than HCMV, the transfected cells were incubated for 3 days to
allow efficient knockdown of target gene. The cells were then
infected with HSV-1 strain F at a multiplicity of 0.02 pfu/cell and
media were harvested 24 hours after infection. The yield of
HCMV and HSV in the media was determined by infectious focus
assay. Briefly, fresh MRC5 cells were infected with different
dilutions of viruses and fixed 24 hours after HCMV or 4 hours
after HSV-1 infection with methanol at 220uC. Foci were
identified using mouse monoclonal primary antibodies to HCMV
immediate early IE1 protein (1B12) [54] or HSV-1 immediate
early ICP4 protein [67] and a goat anti-mouse Alexa Fluor 488-
conjugated secondary antibody (Invitrogen).
Western blot analysis
MRC5 cells were seeded into 6-well dishes and transfected at
70% confluence as described above. HFF cells were grown to
confluence, serum starved for 24 hours and infected at 3 pfu/cell
with HSV-1 (F strain). At selected times post transfection of
MRC5 cells and infection of HFFs, cells were washed with
phosphate-buffered saline (PBS), harvested and stored at 280uC.
Cells were lysed in RIPA-light buffer (50 mM Tris-HCl, pH 8.0,
1% NP-40, 0.1% SDS, 150 mM NaCl, 0.1% Triton X-100,
5 mM EDTA) with protease inhibitors (Roche Applied Science),
and protein concentrations were determined by Bradford assay.
Proteins were separated by 10% SDS-containing polyacrylamide
gel electrophoresis and transferred to nitrocellulose membranes.
Membranes were probed with a primary rabbit polyclonal
antibody directed against pyruvate carboxylase (NBP1-49536,
Novus) at a dilution of 1:1000 in PBS-T and 1% nonfat milk. After
washing with PBS-T, membranes were probed with goat anti-
rabbit HRP-coupled secondary antibodies diluted 1:5000 in PBS-
T containing 1% milk. Proteins were visualized by chemilumi-
nescence using the ECL detection system (Amersham).
Tests of statistical significance
All p-values were calculated by two-tailed, non-paired T-test.
Accession numbers
Pyruvate carboxylase (PC): P11498, aspartate transaminase 2
(GOT2): P00505, carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase (CAD): P27708, HSV-1
dUTPase (UL50): P10234, HSV-1 uracil-DNA glycosylase (UL2):
P10186, HSV-1 thymidine kinase (UL23): P03176.
Supporting Information
Figure S1 Steady state metabolite levels measured in
MRC5, HFF, ARPE19 and Vero cells. The heatmaps show
levels of metabolites measured in biological replicates for each cell
type (numbered), normalized by packed cell volume and expressed
relative to the average level of the particular metabolite across all
cell types. Ratios are log transformed and plotted on a color scale.
Metabolites in panel (A) are clustered by uncentered Pearson
correlation, and in panel (B) they are presented in the same order
as in Figure 1. HFFs and MRC5s were confluent for 4 d and
serum starved for 24 h prior to analysis. ARPE19 and Vero cells
were 80% confluent and actively replicating in the presence of
dialyzed serum at the time of extraction. Rows correspond to
metabolites measured either by LC-high resolution MS or LC-
triple quadrupole MS/MS (those measured by triple quadruople
are marked ‘‘QQQ’’). Columns correspond to biological repli-
cates.
(TIF)
Figure S2 One-step viral growth curves of HCMV and
HSV-1. Supernatants of cells, which were extracted for
metabolomic analysis, were collected and the titered by TCID50
limiting dilution assay. Virus titers at various hours post infection
are plotted on a log scale (mean 61 s.d.; n=2).
(TIF)
Figure S3 Divergent metabolic profiles of HCMV and
HSV-1 infected cells. This figure is a replicate of Figure 1 of the
main text, except it is presented using a yellow-blue color scale for
readers with difficulty distinguishing red-green hues.
(TIF)
Figure S4 Singular value decomposition of the metabo-
lome matrix shown in Figure 1. (A) Vectors were ranked
based on the percent of information they accounted for, and the
top 25 vectors were plotted on a color scale. The first three rows
correspond to the vectors plotted in Figure S4B. (B) The three
most significant characteristic vectors. The signal of each
characteristic vector is plotted versus time. The vectors include
entries for each time point during the eight infection time courses.
Time courses are arranged in the same order as in Figure 1. Cell
types, virus strains and increasing hpi are indicated on the figure.
Time points were 3, 24, 48, 72, 96 hpi for HCMV, with also a
120 hpi sample for the infection of ARPE19 cells, and 3, 6, 9, 12,
15, 18, 21 and 24 hpi for HSV-1. The first vector (generic
response to infection) accounts for 16% of the information from
the dataset, while the second (virus specific response) captures
12%. The third vector accounts for 6% of the information in the
matrix, and highlights the differential metabolic response to HSV-
1 in Vero cells (the last segment of the eight).
(TIF)
Figure S5 HSV-1 induced anapleurotic flux into malate.
Levels of various labeled forms of malate expressed as percent of
the total malate pool upon switching HSV-1 KOS-infected or
mock-treated HFF cells to uniformly
13C-labeled glucose medium
at 12 hpi. The x-axis indicates time after switching to labeled
media (mean 61 s.d.; n=2).
(TIF)
Figure S6 Effect of inhibiting acetyl-CoA carboxylase on
HCMV and HSV-1 replication. (A) Production of infectious
HCMV (AD169) and HSV-1 (KOS) virions in the presence of
carrier (DMSO) or the indicated concentrations of the acetyl-CoA
carboxylase inhibitor TOFA in confluent, serum-starved HFF
cells. Supernatants of cells infected at a multiplicity of infection of
three were collected at 96 hpi from HCMV and 24 hpi from
HSV-1 infected cells, and titered by TCID50 limiting dilution
assay. Virus titers at various hours post infection are plotted on a
log scale (mean 61 s.e.; n (HSV-1)=4, n (HCMV)=3). (B) Cell
Divergent Herpes Virus Metabolic Impact
PLoS Pathogens | www.plospathogens.org 13 July 2011 | Volume 7 | Issue 7 | e1002124viability of HSV-1 infected cells based on trypan blue exclusion at
24 hpi in the presence or absence of TOFA. Trypan blue stain was
added to an aliquot of cells to assess live/dead ratio. For each
condition at least 500 cells were counted.
(TIF)
Table S1 Metabolite levels during the course of HCMV
and HSV-1 infection. Values are normalized by packed cell
volume and expressed relative to levels measured in the equivalent
mock treated host cells. Rows correspond to metabolites measured
either by LC-high resolution MS or LC-triple quadrupole MS/
MS (those measured by triple quadruople are marked ‘‘QQQ’’).
Columns correspond to hours post infection for each of the eight
infection time courses. The host cells and virus strains used in each
time course are indicated. Values are averages of duplicate
independent biological experiments.
(XLS)
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